RECELL® System to be Highlighted at Upcoming Music City SCALE Multidisciplinary Dermatology Meeting

Written by Customer Service on May 9, 2022. Posted in Public Companies.

VALENCIA, Calif. and MELBOURNE, Australia, May 09, 2022 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that a discussion on the RECELL System will be held during the Symposium for Cosmetic Advances & Laser Education (SCALE) multidisciplinary dermatology meeting taking place May 11-15 in Nashville, TN. SCALE is the premier multidisciplinary meeting for aesthetic medicine, plastic surgery and medical dermatology. The presentation will feature Dr. Jeffrey Carter, FACS, Associate Professor of Surgery and Medical Director, UMCNO Burn Center at LSU Health in New Orleans, who will discuss the use of the RECELL System...

ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

Written by Customer Service on May 9, 2022. Posted in Earnings Releases And Operating Results.

SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the first quarter ended March 31, 2022 and provided clinical development and operational highlights. “Throughout the first quarter, we continued to realize significant progress advancing our lead program, evorpacept, through multiple clinical trials,” said Jaume Pons, Ph.D., Founder, President and Chief Executive Officer of ALX Oncology. “Our highlights include dosing the first patient in ASPEN-06, our Phase 2/3 study testing evorpacept in combination with ramucirumab, trastuzumab, and paclitaxel for the treatment of patients with HER2-positive gastric cancer or gastroesophageal...

Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments

Written by Customer Service on May 9, 2022. Posted in Earnings Releases And Operating Results.

Completed resubmission to the FDA of omburtamab BLA DANYELZA® adoption drove a 9% sequential revenue increase to $10.5 million Company issues 2022 full-year DANYELZA® revenue guidance of $45-$50 million Strong cash position with $156.7 million as of March 31, 2022, providing runway through mid-2024 The Company will host a conference call on Tuesday, May 10, 2022, at 9 a.m. ET NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the first quarter 2022. “Y-mAbs had a successful first quarter. We resubmitted the omburtamab BLA, bringing us one step closer to the...

Annexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and Reports First Quarter 2022 Financial Results

Written by Customer Service on May 9, 2022. Posted in Earnings Releases And Operating Results.

Pioneering Upstream Complement-Targeted Platform with Broad Portfolio of Five Differentiated Product Candidates Anticipating Eight Clinical Catalysts Across Robust Pipeline throughout 2022 and 2023 BRISBANE, Calif., May 09, 2022 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced progress across its broad pipeline of product candidates and reported first quarter 2022 financial results. The classical complement cascade is a seminal pathway within the immune system that anchors and drives a host of autoimmune, neurodegenerative and ophthalmic diseases. Annexon’s unique platform targets C1q, the initiator of the pathway that localizes...

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

Written by Customer Service on May 9, 2022. Posted in Earnings Releases And Operating Results.

– More than 75 patients dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; planned global regulatory submissions on track for late 2022- -Initiated two new CTX001 Phase 3 clinical trials in pediatric patients with TDT and SCD- -Enrollment and dosing ongoing for CTX110™, targeting CD19+ B-cell malignancies; additional data expected to report in 2022- -Updates from ongoing CTX120™ and CTX130™ clinical trials anticipated in 1H2022- ZUG, Switzerland and CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the first quarter ended March 31, 2022. “I am pleased with the ongoing momentum across our broad portfolio of innovative gene therapy...

Mesa Air Group Reports Second Quarter Fiscal 2022 Results

Written by Customer Service on May 9, 2022. Posted in Earnings Releases And Operating Results.

PHOENIX, May 09, 2022 (GLOBE NEWSWIRE) — Mesa Air Group, Inc. (NASDAQ: MESA) today reported second quarter fiscal 2022 financial and operating results. Financial Summary Q2: Pre-tax loss of $55.2 million, net loss of $42.8 million or $(1.19) per diluted share. Adjusted net loss1 of $10.3 million or $(0.29) per diluted share. Adjusted net loss excludes a $39.5 million (pre-tax) non-cash charge related to 12 CRJ aircraft held for sale. Quarter Highlights: Mesa took delivery of its third 737-400F freighter aircraft in the quarter. Added an additional E175 flight simulator. Fiscal Year Q2 Results: Mesa’s Q2 FY22 results reflect a net loss of $42.8 million, or $(1.19) per diluted share, compared to net income of $5.7 million, or $0.14 per diluted share for Q2 FY21. Mesa’s Q2 FY22 adjusted pre-tax loss1 was $13.1 million versus...

Aptose Reports Results for the First Quarter 2022

Written by Customer Service on May 9, 2022. Posted in Earnings Releases And Operating Results.

Expands HM43239 dose cohort at 160 mg Headway with luxeptinib “G3” formulation in patients Conference call and webcast at 5:00 pm ET today SAN DIEGO and TORONTO, May 09, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced financial results for the three months ended March 31, 2022 and provided a corporate update. The net loss for the quarter ended March 31, 2022 was $11.5 million ($0.12 per share) compared with $16.2 million ($0.18 per share) for the quarter ended March 31, 2021. Total cash and cash equivalents and investments as of March 31, 2022 were $69.5 million. Based on current operations, Aptose expects that cash on hand and...

FibroGen Reports First Quarter 2022 Financial Results

Written by Customer Service on May 9, 2022. Posted in Earnings Releases And Operating Results.

Completed enrollment in ZEPHYRUS-1 Phase 3 study of pamrevlumab in idiopathic pulmonary fibrosis 1Q 2022 revenue of $60.8M, growth of 58% vs. 1Q 2021 Significant roxadustat volume growth in China in first quarter 2022 offsetting NRDL price reduction SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2022 and provided an update on the company’s recent developments. “We continue our progress in advancing pamrevlumab in three high value indications and are delighted to have completed enrollment of the ZEPHYRUS-1 Phase 3 study in idiopathic pulmonary fibrosis,” said Enrique Conterno, Chief Executive Officer, FibroGen. “In addition, roxadustat is off to a strong start in 2022 in China with significant year over year volume growth.” Recent Developments: Completed...

CarLotz Announces First Quarter Fiscal 2022 Financial Results

Written by Customer Service on May 9, 2022. Posted in Earnings Releases And Operating Results.

First Quarter Revenue Grew 11% versus Last Year to $63.0 millionFirst Quarter Retail Unit Sales of 2,270First Quarter F&I Revenue Grew 138% versus Last Year RICHMOND, Va., May 09, 2022 (GLOBE NEWSWIRE) — CarLotz, Inc. (the “Company” or “CarLotz”; NASDAQ: LOTZ), a leading consignment-to-retail used vehicle marketplace, today announced financial results for the first quarter ended March 31, 2022. First Quarter 2022 Financial Results Net revenue increased 11% to $63.0 million from $56.6 million in the same period in 2021 Retail unit sales were 2,270 compared to 2,554 in the same period in 2021 Finance & insurance revenue increased 138% to $3.7 million from $1.6 million in the same period in 2021 Gross profit was $2.1 million compared to $2.0 million in the same period in 2021 Retail GPU was $827 compared to $1,182 in the...

Gevo Reports First Quarter 2022 Financial Results

Written by Customer Service on May 9, 2022. Posted in Earnings Releases And Operating Results.

Gevo to Host Conference Call Today at 4:30 p.m. EDT/2:30 p.m. MDT ENGLEWOOD, Colo., May 09, 2022 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO) (“Gevo”, the “Company”, “we”, “us” or “our”) today announced financial results for the first quarter of 2022 and recent corporate highlights. Recent Corporate Highlights On January 31, 2022, Gevo announced that it had begun the process of bringing its dairy manure-based renewable natural gas (“RNG”) project online in northwest Iowa and once this facility has reached steady-state production levels of approximately 355,000 MMBTU, its evaluation period by the California Air Resource Board and the Environmental Protection Agency for Low Carbon Fuel Standard (“LCFS”) and Renewable Identification Number (“RIN”)...

Day: May 9, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice